Unichem Laboratories Ltd
NSE: UNICHEMLAB BSE: 506690
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas.[1]
₹377
52W: ₹278 — ₹668
PE 124 · Book ₹344 · +10% vs bookMarket Cap₹2,654 Cr
Stock P/E124Price to Earnings
ROCE7.49%Return on Capital
ROE6.67%Return on Equity
Div. Yield0%Face Value ₹2
Strengths
- +Company is almost debt free.
- +Stock is trading at 1.05 times its book value
- +Company has delivered good profit growth of 37.4% CAGR over last 5 years
Weaknesses
- −Company has a low return on equity of -1.02% over last 3 years.
- −Earnings include an other income of Rs.293 Cr.
- −Company has high debtors of 157 days.
Shareholding Pattern
Promoters70.22%
FIIs1%
DIIs10.63%
Public18.14%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% |
| FIIs | 0.89% | 0.94%▲0.0 | 1.05%▲0.1 | 0.98%▼0.1 | 0.98% | 0.99%▲0.0 | 0.99% | 1%▲0.0 |
| DIIs | 11.57% | 11.65%▲0.1 | 11.63%▼0.0 | 11.32%▼0.3 | 10.92%▼0.4 | 10.74%▼0.2 | 10.73%▼0.0 | 10.63%▼0.1 |
| Public | 17.32% | 17.17%▼0.1 | 17.11%▼0.1 | 17.47%▲0.4 | 17.88%▲0.4 | 18.04%▲0.2 | 18.05%▲0.0 | 18.14%▲0.1 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 334 | 362 | 399 | 390 | 437 | 448 | 461 | 384 | 357 | 315 |
| Expenses | 341 | 343 | 369 | 350 | 372 | 374 | 386 | 359 | 349 | 314 |
| Operating Profit | -7 | 19 | 31 | 40 | 64 | 74 | 75 | 26 | 8 | 1 |
| OPM % | -2% | 5% | 8% | 10% | 15% | 17% | 16% | 7% | 2% | 0% |
| Net Profit | -31 | 69 | -115 | 21 | 43 | 47 | 51 | -2 | -40 | 216 |
| EPS ₹ | -4.38 | 9.84 | -16.33 | 3.05 | 6.16 | 6.66 | 7.27 | -0.26 | -5.67 | 30.69 |
AI Insights
Revenue Trend
TTM revenue at ₹1,517Cr, down 12.6% YoY. OPM at 7%.
Debt Position
Borrowings at ₹90Cr. Debt-to-equity ratio: 0.04x. Healthy balance sheet.
Capex Cycle
CWIP at ₹79Cr (6% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 10.63% (+0.98pp change). FIIs: 1% (-0.62pp change). Promoters hold 70.22%.
Margin & Efficiency
ROCE declining from 19% (Mar 2014) to 7% (Mar 2025). Working capital days: 202.
Valuation
PE 124x with 7.49% ROCE. Price is 10% above book value of ₹344. Dividend yield: 0%.
Recent Announcements
- Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended March 31, 2026, And Audited Financial Results (Standalone And Consolidated) For The Year Ended March 31, 2026. 6 May - Board meeting on May 22, 2026 to approve Q4 FY26 and FY26 financial results.
- Announcement Under Reg. 30 - Product Recall 12 Apr - On 12 April 2026, Unichem's U.S. subsidiary recalled Buspirone Hydrochloride Tablets 5 mg due to OOS assay results.
- Announcement under Regulation 30 (LODR)-Credit Rating 10 Apr - ICRA reaffirmed A+ rating for Unichem Laboratories’ Rs. 180 crore bank facilities on 9 April 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 30 Mar
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse